These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18714563)

  • 1. Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS study.
    Longatto-Filho A; Roteli-Martins C; Hammes L; Etlinger D; Pereira SM; Erzen M; Branca M; Naud P; Derchain SF; Sarian LO; Matos J; Gontijo R; Lima T; Maeda MY; Tatti S; Syrjänen S; Syrjänen K
    Eur J Gynaecol Oncol; 2008; 29(4):327-32. PubMed ID: 18714563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
    Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
    Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among latin american women <35 and > or =35 years of age: experience from the Latin American Screening Study.
    Syrjänen K; Derchain S; Roteli-Martins C; Longatto-Filho A; Hammes LS; Sarian L;
    Acta Cytol; 2008; 52(6):641-53. PubMed ID: 19068666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of screening performance of HPV DNA test on specimens from different sites of the female genital tract].
    Zhang S; Kang L; Liu B; Cui J; Chen F; Liu X; Wang H; Chen W
    Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):389-93. PubMed ID: 25030599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
    Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
    J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
    Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
    Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV detection in a self-collected vaginal swab combined with VIA for cervical cancer screening with correlation to histologically confirmed CIN.
    Kamal EM; El Sayed GA; El Behery MM; El Shennawy GA
    Arch Gynecol Obstet; 2014 Dec; 290(6):1207-13. PubMed ID: 25009070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-sampling of vaginal fluid and high-risk human papillomavirus testing in women aged 50 years or older not attending Papanicolaou smear screening.
    Lindell M; Sanner K; Wikström I; Wilander E
    BJOG; 2012 Jan; 119(2):245-8. PubMed ID: 22017806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled analysis of a self-sampling HPV DNA Test as a cervical cancer primary screening method.
    Zhao FH; Lewkowitz AK; Chen F; Lin MJ; Hu SY; Zhang X; Pan QJ; Ma JF; Niyazi M; Li CQ; Li SM; Smith JS; Belinson JL; Qiao YL; Castle PE
    J Natl Cancer Inst; 2012 Feb; 104(3):178-88. PubMed ID: 22271765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: Implications for vaginal self-collection.
    Belinson JL; Hu S; Niyazi M; Pretorius RG; Wang H; Wen C; Smith JS; Li J; Taddeo FJ; Burchette RJ; Qiao YL
    Int J Cancer; 2010 Sep; 127(5):1151-7. PubMed ID: 20039323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening for cervical cancer in high-risk populations: DNA pap test or Hybrid Capture II test alone?
    Miranda Pereira SM; Castelo A; Makabe S; Utagawa ML; Di Loreto C; Sakamoto Maeda MY; Marques JA; Santoro CL; Filho AL; Das Dores GB
    Int J Gynecol Pathol; 2006 Jan; 25(1):38-41. PubMed ID: 16306782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.
    Sellors JW; Lorincz AT; Mahony JB; Mielzynska I; Lytwyn A; Roth P; Howard M; Chong S; Daya D; Chapman W; Chernesky M
    CMAJ; 2000 Sep; 163(5):513-8. PubMed ID: 11006761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of detection sensitivity for human papillomavirus between self-collected vaginal swabs and physician-collected cervical swabs by electrochemical DNA chip.
    Nilyanimit P
    Asian Pac J Cancer Prev; 2014; 15(24):10809-12. PubMed ID: 25605181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term results of follow-up after HPV self-sampling with devices Qvintip and HerSwab in women non-attending cervical screening programme.
    Bokan T; Ivanus U; Jerman T; Takac I; Arko D
    Radiol Oncol; 2021 Jan; 55(2):187-195. PubMed ID: 33764704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia.
    Crosbie EJ; Bailey A; Sargent A; Gilham C; Peto J; Kitchener HC
    J Clin Microbiol; 2015 Nov; 53(11):3553-9. PubMed ID: 26338859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
    Syrjänen K
    Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
    De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
    J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile.
    Ferreccio C; Barriga MI; Lagos M; Ibáñez C; Poggi H; González F; Terrazas S; Katki HA; Núñez F; Cartagena J; Van De Wyngard V; Viñales D; Brañes J
    Int J Cancer; 2013 Feb; 132(4):916-23. PubMed ID: 22684726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.